Innovent Biologics, Inc. announced that the clinical results of CT103A, the potential best-in-class therapy of fully-human BCMA CAR-T co-developed by Innovent and Nanjing IASO Biotherapeutics, was presented by oral presentation and poster at two of the most prestigious clinical meetings in the worlds of hematology and oncology, the 24th Congress of the European Hematological Society and the American Society of Clinical Oncology Annual Meeting 2019 in Chicago Illinois.
June 17, 2019
· 6 min read
